
Maker of @Thoraguard. Supporter of great Physicians and Nurses. Improving surgical drainage in cardiothoracic surgery to improve outcomes.
Omaha, NE
Joined July 2016
- Tweets237
- Following95
- Followers74
- Likes240
Pinned Tweet
Centese is a start-up medical device company focused on solving the limitations of surgical drainage in the field of #Cardiac and #Thoracic #Surgery. Follow @Thoraguard or visit our website: centese.com
Centese, Inc. retweeted
Innovation in postoperative care starts with listening to the clinicians advancing it every day, such as Dr. Jack Boyd of Stanford Medicine.
Contact us to start your pilot program today and join leading surgeons like Dr. Boyd in embracing the next generation of OR innovation.
Centese, Inc. retweeted
Replying to @ERASCardiac
@ERASCardiac recommends maintaining chest tube patency without breaking the sterile field, a recommendation reflected in Thoraguard’s automated line clearance and digital monitoring.*
Learn more at Centese.com.
*Obafemi OO, et al. JTCVS Open. 2022.
Centese, Inc. retweeted
As we recognize #WorldLungDay and #WorldHeartDay this September, we're celebrating the surgeons, nurses, and care teams advancing heart and lung health every day.
Thank you to the clinicians whose expertise and dedication continue to move patient care forward!
Centese, Inc. retweeted
With 96% of users reporting better access to clinically relevant data,* #Thoraguard helps provide the insights clinicians need to guide chest tube management with confidence.
Learn how we’re advancing digital drainage at Centese.com.
*Geraci TC, et al. 2022.
Centese, Inc. retweeted
#ERAS strongly recommends chest tube patency management following cardiac surgery.*
#Thoraguard was designed to support this guidance through advanced digital drainage capabilities.
Learn more at Centese.com/resources.
*Engelman DT, et al. JAMA Surgery. 2019.
Centese, Inc. retweeted
As surgery continues evolving toward smarter clinical workflows and data-driven decision-making, Centese is helping redefine postoperative management through actionable insights, improved recovery , and better outcomes.
Learn more at Centese.com.
Centese, Inc. retweeted
By utilizing Thoraguard with #SmartCheck, more chest tubes were safely removed within 4-12 hours of surgery compared to Gen 1 digital systems.*
Discover more about what sets Thoraguard apart at Centese.com.
*McCormack AJ, et al. JTCVS Open. 2023.
Centese, Inc. retweeted
Built to inform real-world conversations and evolving best practices, Centese’s Resources page brings together clinical papers, implementation materials and educational content to support #cardiothoracic surgeons and care teams.
Visit Centese.com/resources to see all resources.
Centese, Inc. retweeted
While legacy chest drainage systems often lack the innovation to support early chest tube removal, #Thoraguard provides real-time insights, automated self-clearing chest tubes, and SmartCheck Clinical Decision Intelligence.
Learn more at Centese.com.
Centese, Inc. retweeted
20K patients treated and counting: a proud new milestone for Centese.
What began as a mission to improve surgical outcomes has evolved into a rapidly scaling platform helping hospitals accelerate cardiothoracic recovery.
Learn more at Centese.com.
Centese, Inc. retweeted
Clinical research shows air leak assessments can vary with analog drainage systems.*
Thoraguard with SmartCheck™ technology adds data-driven clinical decision support to chest tube management. Learn more at Centese.com.
*McGuire, et al. ICTS. 2015.
Centese, Inc. retweeted
We’re back from the @AATSHQ Annual Meeting, where leaders across cardiothoracic surgery came together to advance the future of patient care.
Thank you to the physicians, partners, and teams who connected with us to learn about #Thoraguard during the meeting!
Centese, Inc. retweeted
Centese participated in a special session at @AATSHQ with partners of the @ERASCardiac Society.
We’re committed to supporting goals advancing recovery and optimizing patient outcomes with solutions like Thoraguard, and we’re glad to be part of the conversation!
Centese, Inc. retweeted
We can’t wait to join our peers at the @AATSHQ 2026 Annual Meeting this May 2-5 in Chicago!
Visit us at Booth 1402 to learn more about Thoraguard + SmartCheck technology.
Schedule your meeting here: centese.com/thoracic-surgery…
Centese, Inc. retweeted
Legacy systems often rely on manual checks and subjective assessment. Thoraguard’s automated self-clearing tubes and SmartCheck™ advance chest drain management by translating data and intelligence into insights that inform decision making.
Learn more at Centese.com
Centese, Inc. retweeted
In a 2024 study, Thoraguard’s automated line-clearing chest tubes led to a significant reduction in #POAF compared with conventional drainage, along with lower rates of morbidity and mortality.*
Learn more at Centese.com.
*Heng EE, et al. JTCVS Open. 2024.
Centese, Inc. retweeted
This #NationalDoctorsDay, we thank the physicians whose evidence-based decisions shape recovery and patient outcomes.
“Thoraguard is the most precise and reliable chest drain on the market. It provides tremendous value to our patients and hospital.” - Dr. Robert Cerfolio
Centese, Inc. retweeted
This #CertifiedNursesDay, we recognize the contributions of nurses and the role they play in cardiothoracic surgical recovery.
Learn how #Thoraguard can support clearer communication across the care team and more consistent recovery at Centese.com.
@ANANursingWorld
Centese, Inc. retweeted
Great connecting with the cardiothoracic community at #STS2026!
Proud to share the latest advancements in Thoraguard, including intelligent support like SmartCheck™.
@STS_CTsurgery
Centese, Inc. retweeted
SmartCheck™ technology with Thoraguard advances the capabilities of digital drainage with data-driven clinical decision support that helps teams interpret drainage information in context.
Learn more about SmartCheck at Centese.com.

















